SCHEMBL5653775

SCHEMBL5653775

CCOC(=O)c1sc2[nH]c(=O)ccc2c1-c1ccc(F)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 1/20 0.41
DBF4 Q9UBU7 1/20 0.41
ALDH1A1 P00352 6/20 0.40
MAPT P10636 5/20 0.40
KDM4E B2RXH2 4/20 0.40
HPGD P15428 3/20 0.40
TSHR P16473 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HSD17B10 Q99714 2/20 0.40
ALOX15 P16050 1/20 0.40
TRPM8 Q7Z2W7 2/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
LMNA P02545 4/20 0.37
PRKCZ Q05513 1/20 0.36
GLA P06280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5648088 0.85 MAPT (0.49) ALDH1A1MAPTKDM4EHPGDNPC1
SCHEMBL5651378 0.78 ALDH1A1 (0.50) CDC7DBF4ALDH1A1MAPTKDM4E
SCHEMBL1266729 0.74 MAPT (0.46) ALDH1A1MAPTKDM4EHPGDTSHR
SCHEMBL5651315 0.74 MAPT (0.43) CDC7DBF4ALDH1A1MAPTKDM4E
SCHEMBL2956431 0.73 DHODH (0.46) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL5653909 0.73 ALDH1A1 (0.39) CDC7DBF4ALDH1A1MAPTKDM4E
SCHEMBL5653071 0.70 TRPV4 (0.41) ALDH1A1MAPTKDM4EHPGDTSHR
SCHEMBL4140622 0.69 MMP2 (0.46) MAPTNPC1RAB9AKMT2AMMP1
Hydrochloric Acid SCHEMBL5653006 0.69 TRPV4 (0.40) ALDH1A1MAPTKDM4EHPGDTSHR
SCHEMBL2948992 0.69 DHODH (0.51) ALDH1A1MAPTKDM4EHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 CDC7 965/4885DBF4 2604/4885ALDH1A1 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.